Al-Madina Pharmaceuticals Limited announcements
60 Dhaka Stock Exchange announcements for Al-Madina Pharmaceuticals Limited (AMPL) since 2023: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2023 (16).
- The company has informed that it has developed and completed agreement with two buyers Hejaj Ltd., Afghanistan and Al-Zu
The company has informed that it has developed and completed agreement with two buyers Hejaj Ltd., Afghanistan and Al-Zubaidi Stores, Yemen to export its pharma products.
- The company has informed that any surplus amount resulting from the variance between the budgeted QIO Fund and its actua
The company has informed that any surplus amount resulting from the variance between the budgeted QIO Fund and its actual utilization shall be allocated towards factory development, in accordance with the decision of the shareholders. The resolution has been decided by public shareholders and subject to necessary regulatory approval within December 31, 2024.
- Trading of the shares of the company will resume on 31.10.2023.
Trading of the shares of the company will resume on 31.10.2023.
- Trading of the shares of the company will remain suspended on record date i.e., 30.10.2023.
Trading of the shares of the company will remain suspended on record date i.e., 30.10.2023.
- Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 26.10.2023 to 29.10.2023 and trading of the shares will remain suspended on record date i.e., 30.10.2023.
- The Board of Directors has recommended 10\% cash dividend excluding sponsors and/or directors for the year ended June 30
The Board of Directors has recommended 10\% cash dividend excluding sponsors and/or directors for the year ended June 30, 2023. Quantity of securities of Directors: 1,42,50,000 shares. Date of AGM: 14.12.2023, Time: 11:30 AM, Venue: Digital Platform through the link: https://almadinapharma.bdvirtualagm.com. Record Date: 30.10.2023. The Company has reported EPS (Basic/Weighted Average) of Tk. 1.57, EPS (Diluted) of Tk. 1.23 for the year ended June 30, 2023 as against Tk. 1.30 and Tk. 0.97 (cont.)
- (Continuation news of AMPL): respectively for the year ended June 30, 2022. The Company has also reported NAV per share
(Continuation news of AMPL): respectively for the year ended June 30, 2022. The Company has also reported NAV per share (with revaluation) of Tk. 19.82, NAV per share (without revaluation) of Tk. 13.00 and NOCFPS of Tk. (1.64) for the year ended June 30, 2023 as against Tk. 21.65, Tk. 12.63 and Tk. (0.55) respectively for the year ended June 30, 2022. (end)
The first part of this announcement is missing from the archive. - There will be no price limit on the trading of the shares of the Company today (10.10.2023) following its corporate decl
There will be no price limit on the trading of the shares of the Company today (10.10.2023) following its corporate declaration. However, the floor price shall be applicable accordingly.
- The company has further informed the following: Quantity of shares of General Shareholders: 61,50,000 shares. Proposed d
The company has further informed the following: Quantity of shares of General Shareholders: 61,50,000 shares. Proposed dividend amount: Tk. 61,50,000.00
- As per Regulation 17(1) of the Dhaka Stock Exchange (Listing of Small Capital Companies) Regulations, 2019, the Company
As per Regulation 17(1) of the Dhaka Stock Exchange (Listing of Small Capital Companies) Regulations, 2019, the Company has informed that a meeting of the Board of Directors will be held on October 09, 2023 at 5:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2023.
- In response to a DSE query dated June 22, 2023, the company has informed that there is no undisclosed price sensitive in
In response to a DSE query dated June 22, 2023, the company has informed that there is no undisclosed price sensitive information of the company for recent unusual price hike and increase in volume of shares.
- Trading of the shares of Al-Madina Pharmaceuticals Limited will commence at DSE from May 29, 2023 under SME platform. DS
Trading of the shares of Al-Madina Pharmaceuticals Limited will commence at DSE from May 29, 2023 under SME platform. DSE Trading Code for Al-Madina Pharmaceuticals Limited is \"AMPL\" and DSE Company Code is \'68004\' under \'Pharmaceuticals & Chemicals\' sector.
- Company News: Al-Madina Pharmaceuticals Limited: (Quarterly): As per un-audited Q2 financial statements, profit after ta
Company News: Al-Madina Pharmaceuticals Limited: (Quarterly): As per un-audited Q2 financial statements, profit after tax was BDT 17.39 million and basic EPS of BDT 1.13 for the 06 (six) months period July-December, 2022 against profit after tax of BDT 18.48 million and basic EPS of BDT 1.24 for the same period of the previous year, July-December 2021. However, Post-QIO Basic EPS for the current 06 (six) months period July-December, 2022 would be BDT 0.85. (cont.1)
- (Continuation news of Q2 Financials of Al-Madina Pharmaceuticals Limited): Pre-QIO weighted average paid-up number of sh
(Continuation news of Q2 Financials of Al-Madina Pharmaceuticals Limited): Pre-QIO weighted average paid-up number of shares for the period July-December 2022 was 15,400,000 which was 14,910,870 for the same period of the previous year. However, Post-QIO paid-up number of shares would be 20,400,000. Pre-QIO Net Asset Value (NAV) per Share With and Without Revaluation Surplus (considering Pre-QIO paid up shares) (cont.2)
The first part of this announcement is missing from the archive. - (Continuation news of Q2 Financials of Al-Madina Pharmaceuticals Limited): was BDT 22.78 and BDT 13.75 respectively as o
(Continuation news of Q2 Financials of Al-Madina Pharmaceuticals Limited): was BDT 22.78 and BDT 13.75 respectively as on 31 December 2022, whereas the same would be BDT 19.65 and BDT 12.83 on the same date (considering Post-QIO paid up shares). (end)
The first part of this announcement is missing from the archive. - DSE NEWS: The Stock Brokers, Merchant Bankers and Portfolio Managers are requested to abstain from providing loan facili
DSE NEWS: The Stock Brokers, Merchant Bankers and Portfolio Managers are requested to abstain from providing loan facilities to purchase securities of Al-Madina Pharmaceuticals Limited in between 1st to 30th trading day starting from today i.e., May 29, 2023 as per BSEC Directive No. BSEC/CMRRCD/2009-193/32 dated December 26, 2021.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.